Table 2.

Baseline characteristics of patients treated for newly diagnosed BL in Lilongwe, Malawi, by initial treatment regimen

	Total no. of patients	CHOP (n = 22)						More intensive regimen (n = 9)						P
		No.	%	Median	Range	Mean	SD	No.	%	Median	Range	Mean	SD
Male sex	31	15	68					6	67					1
Age, y	31			20	15-57					16	15-55			.65
Body mass index, kg/m2	26					18.9	4.9					17.9	1.5	.65
B symptoms	31	13	59					7	78					.43
Ann Arbor stage III to IV	31	18	82					6	67					.38
ECOG PS ≥2	31	13	59					3	33					.25
aaIPI	28													1
1		5	24					2	28
2		9	43					3	43
3		7	33					2	28
Central nervous system involvement	31	5	23					0	0					.27
Bone marrow involvement	21	3	21					1	14					1
Abdominal disease	31	14	64					6	67					1
Bulky disease (>10 cm)	20	11	73					4	80					1
HIV positive	31	9	41					3	33					1
CD4 count, cells per μL	12			130	29-605					238	39-272			.78
HIV viral load, detectable >400 copies per μL	12	4	44					0	0					.49
White blood cells, ×109/L	31			7.2	2.8-20.3					7.4	2.1-11.7			.91
Hemoglobin, g/dL	31			11.0	1.6-14.8					9.9	7.7-11.7			.13
Platelets, ×109/L	31			314	139-859					438	157-635			.24
Creatinine, mg/dL	29			0.6	0.3-2.4					0.5	0.4-1.7			.41
Bilirubin, mg/dL	28			0.4	0.2-2.0					0.4	0.2-1.4			.72
Albumin, g/dL	22					3.7	2.7-5.8					3.4	2.3-4.4	.38
LDH ratio per ULN	28			2.2	0.4-20					2.2	1.0-5.1			.98
LDH >2× ULN	28	14	33					5	71					1.0